Almac optimised workflow for the Illumina TruSeq® RNA Exome Panel for use in biomarker discovery and translational research.
Current RNA panel solution – RUO
Almac Diagnostic Services has a proven ability to discover, develop and validate high quality, innovative RNA-based biomarkers with an extensive track record in establishing assays across key regulatory standards. We are offering the optimised RNA Exome Panel initially as Research Use Only (RUO) – not for use in Diagnostic procedures.
claraT – unique gene expression report

The claraT report is a unique software-driven solution, classifying biologically relevant gene expression signatures into a comprehensive, easy-to-interpret report.
Offered as a cost-effective reporting solution from samples processed using the Almac optimised RNA Exome Panel. Helping you to maximise the understanding of your data set, whilst saving valuable research time.
Compatible with both Single RNA and Dual RNA/DNA extraction protocols
Almac offer both high quality single RNA extractions and a dual RNA/DNA extraction protocol (recommended kits both Qiagen) for the optimised RNA Exome biomarker discovery offering. Dual extraction facilitates simultaneous generation of RNA Exome data and WES data from a single sample, therefore conserving valuable sample material.
Find out more on our Whole Exome Sequencing Service.
Contact Us
Ask for a quote for our claraT gene expression report
The Platform
The Almac RNA Exome Panel is an optimised Next Generation Sequencing (NGS) solution built on the Illumina TruSeq® RNA Exome chemistry and run on the NextSeq500, NextSeq550 and NovaSeq6000 that detects RNA gene expression from solid tumour samples.
The platform covers approximately 99% of the RefSeq Exome with sequencing data and easily interpretable gene expression matrices for use in biomarker discovery and translational research across multiple disease indications.
Data analysis and reporting is performed using an Almac customised bioinformatics pipeline implemented on Illumina Connected Analytics (ICA), a global leader in biomedical informatics and data management. Illumina Connected Analytics (ICA) is a cloud-based NGS solution which ensures scalability and security of project data. A significant benefit of utilising Illumina Connected Analytics (ICA) within this offering is the flexibility of workflow optimisation and the ability to customise bespoke pipelines for quality control, alignment & expression estimation.
At a Glance
- Illumina enrichment based targeted NGS panel processed on a range of Illumina instruments including the NovaSeq6000 and NovaSeq X Plus.
- Covers >21,000 genes from the RefSeq Exome
- Optimised for use with FFPE tissue for analysis of RNA
- Compatible with challenging sample types
- Established process controls included within each processing batch
- Robust quality control pipelines optimised for core quality metrics including:
- -sample and library QC
- -sequencing run QC
- -post sequencing/ alignment QC
- Results in highly repeatable and reproducible gene expression data in comparison to other RNA expression platforms.
Key Benefits
- High quality service for profiling gene expression data from solid tissue types
- Optimised protocol maximising on pass rates and sequencing data quality from challenging sample types, reducing sample attrition
- Highly repeatable and reproducible gene expression data
- Provision of raw data for research use
- Requires minimal sample material
- Evaluation of multiple biologies on one panel
- Almac customised bioinformatics pipeline using a cloud-based solution (Illumina Connected Analytics (ICA)
- claraT: cost effective solution, producing an easy to interpret gene expression report.
Key Facts
Metric | RNA Exome Discovery Panel |
---|---|
Tissue Type | For FFPE, tissue should be macrodissected. 10 x 5 µm FFPE sections with a tissue area >1cm² and high tumour content >10% viable cells. Specific guidelines will be provided on a per-project basis |
Recommended Tissue Requirements | 1mm3 FFPE Tissue (macrodissected) |
Input Material | RNA |
Recommended Input Requirements | 100- 500 ng (dependent on sample quality defined by DV200 |
Raw Data Provided | Yes- FASTQ and BAM files |
Customisable Reporting | Yes |
Bioinformatics Applications | Cloud based RNAseq pipeline delivered via Illumina Connected Analytics (ICA) |
In the Press
Almac Group Launches Upgraded Version of claraT – A Unique, Software-driven Gene Expression Report
Almac’s unique gene expression report enables cancer researchers to discover exciting new insights
Almac Group Announces Winners of claraT Grant Programme for Academia
Almac Diagnostic Services’ claraT Report Assists Researchers In Uncovering New Oncology Findings
Almac Diagnostic Services updates claraT report with significant new content for cancer research

claraT classifies multiple publically available gene expression signatures and single gene targets linked to multiple key biologies, alongside Almac’s own proprietary assays, according to the well-established 10 Hallmarks of Cancer. The claraT report is a pan-cancer solution generated from raw gene expression data, utilising Almac’s RNA-Sequencing Service.